Search research articles
Contact Us
Filters
Showing results (1-10 of 64) with videos related to
Page
of 7
Sort By:
Current Oncology Reports
|
January 20, 2021
Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer : In response to: Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions published by Di Maria Jiang et al. Current Oncology Reports 2020, https://doi.org/10.1007/s11912-020-0880-5
Dirk Böhmer, Arne Grün
Deutsches Arzteblatt International
|
October 30, 2016
In Reply
Dirk Böhmer, Axel Heidenreich, Thomas Wiegel
International Journal of Radiation Oncology, Biology, Physics
|
October 18, 2020
Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
Dirk Böhmer, Stefan Höcht, Thomas Wiegel
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 11, 2019
[Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months.]
Dirk Böhmer, Felix Sedlmayer, Thomas Wiegel, et al.
Urologie (Heidelberg, Germany)
|
October 19, 2022
[Significance of duration of concurrent hormone therapy and definitive radiotherapy]
Dirk Böhmer, Thomas Wiegel, Stefan Höcht, et al.
Urologie (Heidelberg, Germany)
|
February 28, 2023
[Ultrahpyofractionated radiotherapy for prostate cancer-a new standard?]
Stefan Höcht, Dirk Böhmer, Thomas Wiegel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 15, 2009
MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence
Tobias Franiel, Lutz Lüdemann, Matthias Taupitz, et al.
BJU International
|
June 21, 2019
The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer
Detlef Bartkowiak, Alessandra Siegmann, Dirk Böhmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2020
Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer
Pirus Ghadjar, Dirk Böhmer, Stefan Höcht, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
February 6, 2025
Implant geometry and detection rates of prostate fiducial markers after transrectal ultrasound-guided perineal implantation for image-guided 6D-tracking in robotic stereotactic body radiotherapy
Arne Grün, Katharina Heil, Daniel Zips, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 64) with videos related to
Sort By:
Page
of 7
Current Oncology Reports
|
January 20, 2021
Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer : In response to: Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions published by Di Maria Jiang et al. Current Oncology Reports 2020, https://doi.org/10.1007/s11912-020-0880-5
Dirk Böhmer, Arne Grün
Deutsches Arzteblatt International
|
October 30, 2016
In Reply
Dirk Böhmer, Axel Heidenreich, Thomas Wiegel
International Journal of Radiation Oncology, Biology, Physics
|
October 18, 2020
Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
Dirk Böhmer, Stefan Höcht, Thomas Wiegel
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 11, 2019
[Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months.]
Dirk Böhmer, Felix Sedlmayer, Thomas Wiegel, et al.
Urologie (Heidelberg, Germany)
|
October 19, 2022
[Significance of duration of concurrent hormone therapy and definitive radiotherapy]
Dirk Böhmer, Thomas Wiegel, Stefan Höcht, et al.
Urologie (Heidelberg, Germany)
|
February 28, 2023
[Ultrahpyofractionated radiotherapy for prostate cancer-a new standard?]
Stefan Höcht, Dirk Böhmer, Thomas Wiegel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 15, 2009
MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence
Tobias Franiel, Lutz Lüdemann, Matthias Taupitz, et al.
BJU International
|
June 21, 2019
The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer
Detlef Bartkowiak, Alessandra Siegmann, Dirk Böhmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2020
Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer
Pirus Ghadjar, Dirk Böhmer, Stefan Höcht, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
February 6, 2025
Implant geometry and detection rates of prostate fiducial markers after transrectal ultrasound-guided perineal implantation for image-guided 6D-tracking in robotic stereotactic body radiotherapy
Arne Grün, Katharina Heil, Daniel Zips, et al.
Page
of 7